Genzyme's search for a vector

Genzyme's search for a vector

Genzyme Corp.'s decision on Friday to exercise its option to exclusively license Vical Inc.'s cytofectin non-viral vector technology for cystic fibrosis served as a reminder that gene therapy remains at an early stage of development, despite the plethora of ongoing clinical trials.

In addition to VICL's cationic lipid vectors, GENZ is pursuing adenoviral and other viral vector approaches to CF.

GENZ has treated 29 patients to date with a third generation adenoviral vector in a lobar and aerosol lung study. The company is seeing expression of the cystic fibrosis transmembrane conductance regulator

Read the full 952 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE